Impaired DDR is associated with more aggressive PCa, and the identification of crosstalk between AR and DNA-PKcs has ultimately resulted in an ongoing clinical trial assessing the benefit of combination treatment with an experimental DNA-PK inhibitor (CC-115) and enzalutamide (NCT02833883) [84]. The gene discussed is PRKDC; the disease is posterior cortical atrophy.